U.S., Oct. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07215468) titled 'HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study' on Oct. 09.
Brief Summary: TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test the combination of the antibodies as maintenance therapy in HIV infected suppressed individuals discontinuing oral cART for 48 weeks.
Researchers will compare TMB-365/TMB-380 given IV every 8 weeks to continuation of daily oral cART to see if TMB-365/TMB-380 can also maintain viral suppression.
Participants will:
1. Receive TMB-365/TMB-380 i...